|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 67.33 USD | -0.65% |
|
-2.97% | -14.73% |
| Apr. 25 | Cigna to offer Humira rivals with $0 copay at specialty pharmacy | RE |
| Apr. 25 | CVS Health Corporation Opens New Workforce Development and Community Resource Center in Baton Rouge | CI |
(Reuters) - German dialysis specialist Fresenius Medical Care reported on Tuesday a 3% rise in its second-quarter revenue, citing healthy growth in its U.S. dialysis business.
The company confirmed its full-year guidance and still expects sales to rise by 3% to 7%, and adjusted net income change to be in the range of -2% to 2%, after second-quarter revenue came in broadly in line with analysts' expectations in a Refinitiv poll.
(Reporting by Bartosz Dabrowski in Gdynia; Editing by Tomasz Janowski)
Price
|
Change
|
5d. change
|
Capi.
| ||
|---|---|---|---|---|---|
| 132.8 USD | +0.02% | +5.28% | 11.64B | ||
| 37.79 EUR | -3.00% | +3.73% | 12.22B | ||
| 27.18 EUR | -0.51% | +1.99% | 16.44B | ||
| 1st Jan change | Capi. | |
|---|---|---|
| -14.73% | 85.42B | |
| +16.05% | 84.38B | |
| +10.92% | 29.39B | |
| -12.73% | 17.49B | |
| -3.17% | 16.44B | |
| -1.78% | 15.28B | |
| -0.45% | 12.22B | |
| -31.23% | 11.98B | |
| -2.51% | 11.71B | |
| +26.74% | 11.64B |
CVS HEALTH CORPORATION 
